Objective: Combined treatment with psychotherapy and antidepressants is more effective than monotherapies. Recent data show that combined therapy has better results in patients with depression and Axis II codiagnosis. The aim of this study was to compare combined treatment using interpersonal psychotherapy (IPT) with pharmacotherapy alone in patients with depression and borderline personality disorder (BPD).
T reatment options for major depression have been a central issue of psychiatric investigation. Medications and psychotherapy have been extensively studied and used in clinical practice. The efficacy of antidepressant drugs is supported by many placebo-controlled trials and represents the current standard of treatment (1, 2) . Brief psychotherapies are commonly used as antidepressant therapy and have been studied by several authors (3) (4) (5) (6) (7) (8) (9) . IPT ranks among models of psychotherapy that have been effective in treating depressive disorders (10) (11) (12) (13) (14) (15) (16) (17) (18) . Accordingly, IPT has been recommended in the practice guidelines for depression and has been more widely used in clinical practice (1) . Recently, combined therapy (using antidepressant drugs and brief psychotherapy) has been increasingly evaluated and has proven more efficacious than monotherapy in the treatment of depression, particularly in selected clinical populations (that is, chronic or severe depression). Authors reported response rates of 50% to 85% with combined therapy, compared with 35% to 55% with either only drugs or only psychotherapy (19) (20) (21) (22) (23) (24) (25) .
Few systematic investigations have been conducted on combined treatment of patients with depression and comorbid personality disorders. A recent study found that combined therapy is more effective than pharmacotherapy alone in patients with depression and personality disorders (26) . Further, Cyranowski and others treated patients suffering from depression with IPT and found that subjects meeting criteria for a personality disorder more frequently needed adjunctive SSRI treatment to achieve remission of depressive episodes (16) . Although this comorbidity is very common (53% to 85% in BPD samples) (27) (28) (29) (30) (31) and exerts significant effects on severity of depression and social impairment (27, 32, 33) , there are currently no studies that focus on combined treatment of major depression that affects patients with BPD. The use of psychotherapy in treating these patients is central to the investigation of this topic. In our opinion, IPT is a good option as it is both recommended to treat major depression and listed in treatment guidelines among new, promising psychotherapies for BPD (34, 35) .
Aim of the Study
We designed this study to compare the efficacy of combined therapy (that is, a serotonergic antidepressant plus IPT) with monotherapy (that is, an antidepressant) in patients with depression and comorbid BPD.
Methods
The study participants were selected from patients attending the Service for Personality Disorder of the Unit of Psychiatry, Department of Neuroscience, University of Turin. We included consecutive outpatients who received a DSM-IV-TR (36) diagnosis of BPD and then met criteria for a major depressive episode (that is, mild to moderate). Diagnoses were made by an expert clinician and were confirmed using the structured clinical interview for DSM-IV Axis I and II disorders (37, 38) .
We excluded individuals with a lifetime diagnosis of delirium, dementia, amnestic or other cognitive disorders, schizophrenia or other psychotic disorders, and patients whose major depressive episode was an expression of bipolar disorder.
Exclusion criteria also considered a current diagnosis of substance abuse disorder and whether an individual was treated with psychotropic drugs or psychotherapy during the 2 months prior to the study. Female patients of childbearing age were excluded if they were not using an adequate method of birth control (according to the judgment of the clinician).
Written informed consent was obtained from all patients prior to their participation. We followed the Declaration of Helsinki guidelines.
Patients were randomly assigned to 1 of 2 treatment groups: pharmacotherapy alone or combined therapy. Patients underwent their respective treatments for 24 weeks.
Pharmacotherapy
Of the initial 39 participants, 19 patients received fluoxetine 20 mg to 40 mg daily plus clinical management. Initially, fluoxetine was prescribed at a fixed dosage of 20 mg daily with the opportunity to increase the dosage to 40 mg daily beginning in Week 2, depending on clinical judgment. Each patient was given 4 appointments, the first 2 fortnightly and the last 4 monthly. A psychiatrist provided pharmacotherapy and clinical management. 
Combined Therapy
The other 20 patients received fluoxetine plus IPT. IPT consisted of weekly sessions lasting 1 hour and was conducted referring to the Interpersonal Psychotherapy of Depression Manual (39) . Patients in the combined therapy group were treated by a psychotherapist who was not the psychiatrist prescribing the medication and who had 5 years of experience practising IPT. The psychotherapy and the pharmacotherapy started at the same time.
All patients were repeatedly assessed (that is, at baseline, Week 12, and Week 24) with the following measures:
1. A semistructured interview to assess demographic and clinical characteristics.
2. The Severity and Improvement items of the CGI to assess the level of global symptomatology (40).
3. The HDRS and the HARS (41,42).
4. The SAT-P (a self-administered questionnaire consisting of 32 scales that provides a daily life satisfaction profile and can be considered an indicator of subjective quality of life); it considers 5 different factors: psychological functioning; physical functioning; work; sleep, food, and free time; and social functioning (43) . This questionnaire allows analysis of patients' perception of their level of functioning and treatment benefits.
5. The IIP-64, a self-report inventory designed to identify problematic areas in interpersonal relationships (44) . This inventory assesses the severity of interpersonal problems in 8 domains: domineering or controlling, vindictive or self-centred, cold and distant, socially inhibited, nonassertive, overly accommodating, self-sacrificing, and intrusive or needy. The IIP-64 has been widely used to assess psychotherapy outcome (45) (46) (47) (48) and can be used to measure change of interpersonal functioning after IPT.
The assessments were performed by an investigator who was blind to the treatment methods. Remission was defined by a decreased HDRS score ($ 40%), with a final score of # 8, and a score of 1 (that is, very much improved) or 2 (that is, much improved) on the Improvement item of the CGI.
We performed statistical analyses using the software program SPSS version 12.0. Only those patients who completed the study were included in the analysis. We used t tests and chi-square tests to compare demographic and clinical characteristics (that is, age, sex, the Severity item of the CGI, and HDRS and HARS scores) at baseline. We used Pearson's chi-square test to compare the number of respondents between subgroups of patients treated with combined therapy or pharmacotherapy alone. We used the univariate GLM to calculate the effects of 2 factors (that is, the duration and the type of treatment) on each assessment scale score. P values were considered significant when P # 0.05.
Results
Initially, there were 39 patients enrolled in the study. At intake, there were no significant differences between the 2 treatment groups with regard to age, sex, the Severity item of the CGI, and HDRS and HARS scores.
Owing to noncompliance, 7 patients discontinued treatment during the first 3 weeks. Of these individuals, 4 were in the medication-only group, and 3 were in the combined therapy group. We performed statistical analyses on the 32 patients (that is, 16 patients in each group) who completed the 24 weeks of treatment. The sample had a mean age of 26.4, SD 3.7, years. The ratio of men to women was 3 to 5. At the endpoint, 75% (n =12) of combined-treatment patients and 62.5% (n =10) of medication-only patients achieved remission. Statistical comparison with Pearson's test did not show a significant difference (÷ 2 = 0.562, P = 0.446).
Results of the univariate GLM performed on the Severity item of the CGI, HDRS, and HARS results are presented in Table 1 . On each scale, we found that the time factor had a significant effect (P = 0.0005). The treatment factor showed a significant effect (P = 0.005) only on the HDRS, which indicates a higher score change in the subgroup receiving combined therapy.
We applied the GLM to the 5 factors of the SAT-P. The results are presented in Table 2 . There was a significant change in all the factors related to the length of treatments (P < 0.001). We found that the interaction of the time factor and the treatment factor had a significant effect on the psychological functioning factor (P = 0.017): the efficacy of combined therapy was greater in function over the course of treatment. The treatment factor (P = 0.020) and the interaction of the time and treatment factors (P = 0.005) both had significant effects on the social functioning factor: combined therapy was more effective and the difference between treatments increased over time.
Results of the univariate GLM applied to the 8 domains of the IIP-64 are described in Table 3 . Findings differ depending on which domain is considered. Neither time nor treatment factors had a significant effect on any of the following 4 domains: domineering or controlling, nonassertive, overly accommodating, and self-sacrificing. Both the time (P < 0.005) and the treatment factor (P < 0.05) had a significant effect on the intrusive or needy, vindictive or self-centred, and cold or distant domains. These results indicate that combined therapy has more of an impact on these areas than drug therapy. The time factor (P = 0.0005) and the interaction between the time factor and the treatment factor (P = 0.021) both had a significant effect on the socially inhibited factor, which shows that combined therapy had better results and that the difference between treatments increased with the length of therapy.
Discussion
Our study compared combined therapy (that is, fluoxetine plus IPT) with pharmacotherapy alone (that is, fluoxetine) in the treatment of patients with a major depressive episode and preexisting BPD. We chose fluoxetine because it is a widely used antidepressant and it is recommended by APA treatment guidelines for BPD (35, 49) . Our patients were treated with IPT because this approach has been proposed and studied for the treatment of major depressive disorder (5, 39) and is now considered one of the effective psychotherapies for BPD (35, 50) .
The 2 treatment modes do not differ significantly in rates of remission, improvement of global psychopathology, and reduction of anxious symptoms. Significant differences favouring combined therapy have been found in depressive symptoms and in factors related to subjective quality of life and dysfunctional patterns of interpersonal relationships.
Rates of remission do not differ significantly between the combined-treatment group and the pharmacotherapy group (75%, compared with 62.5%). This finding is concordant with a recent metaanalysis conducted by de Mello and others who considered studies of combined therapy using IPT, compared with pharmacotherapy alone, in depressive disorders (18) . Nevertheless, this review did not consider the presence of personality disorders in patients with depression.
Significant differences between treatments in our patients concern symptoms of depression and measures of social and relational functioning. A comparison with the literature data is not easy. Many authors have found that concomitant personality disorders have negative effects on the treatment outcome of patients with major depression, both on depressive symptoms and on social functioning (51) (52) (53) (54) . A study by Kool and others compared combined treatment and pharmacotherapy of depression, examining the effect of personality disorders on differences in clinical response (26) . In patients with concomitant personality disorders, combined therapy was superior to pharmacotherapy in measures of global psychopathology, depressive symptoms, and quality of life. These differences were not found in patients without Axis II comorbidity. We must emphasize at least 2 differences between our study and Kool and others' study: Kool and others provided short psychodynamic supportive psychotherapy, although BPD was only one of the Axis II diagnoses in their sample and only the fourth most frequent.
Regarding subjective quality of life as measured by the SAT-P, our results show that IPT combined with fluoxetine is significantly superior to the antidepressant alone in changing the psychological functioning and the social functioning factors. The first factor deals with self-esteem, psychological autonomy, and problem-solving ability. The second factor refers to the quality of social relations. These results are consistent with recent literature that indicates an improvement in quality of life and social skills both in patients with depression (17, 22, 55, 56) and in patients with BPD treated with combined therapy (34, (57) (58) (59) Our findings on the data collected with IIP-64 are heterogeneous if single domains are considered. The vindictive or self-centred, cold or distant, socially inhibited, and intrusive or needy domains show higher changes over time with combined therapy than with drug therapy. As these domains appear to be related to symptoms of BPD such as fear of abandonment and unstable relationships, we can suggest that the association of IPT with an antidepressant is effective not only at increasing improvement of depressive symptoms but also in modifying dysfunctional relationship patterns that reflect the abnormalities of borderline personality. Conversely, the domineering or controlling and nonassertive domains do not change significantly with either treatment. The case is the same for the overly accommodating and self-sacrificing domains, but it is important to note that scores of these 2 domains are included, according to the manual of the IIP-64, in a norm-based range beginning at baseline (50). It is not clear why some domains of the IIP-64 change significantly after treatment of a depressive episode while others do not. Perhaps the domineering or controlling and nonassertive domains are expressions of BPD features, such as identity disturbance, that are highly persistent and cannot be affected by a 6-month treatment period.
We can propose an overall explanation of the differences between combined treatment and pharmacotherapy alone in patients with BPD and major depression. We suggest that these patients are affected by depressive symptoms as a consequence of maladaptive personality traits that influence mood reaction to interpersonal difficulties. Combining IPT with antidepressant treatment may produce additional effects on these traits and contribute to improvements in depression and relational functioning.
In conclusion, our findings confirm that combined therapy is more effective than pharmacotherapy alone, both on symptoms and on social and relational functioning of patients with BPD and major depressive disorder. If these data were replicated, the combination of a serotonergic antidepressant and IPT could be proposed as a preferred treatment for the large proportion of patients with BPD who suffer from depression. More extensive studies, including a larger sample and a comparison between combined therapy and IPT alone, are needed to confirm these clinical suggestions. Our study is limited by the lack of follow-up assessments to evaluate whether clinical results are maintained over time and whether improved quality of life and relational functioning achieved with combined therapy can influence the prevention of recurrence of depressive episodes. We are currently collecting follow-up data that will be analyzed and presented in a forthcoming paper.
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This study received no funding and no support. Méthodes : Trente-neuf patients externes consécutifs ayant reçu un diagnostic de TPL et présentant un épisode de dépression majeure ont participé à cette étude. Nous les avons affectés au hasard à 1 de 2 groupes de traitement : de 20 mg à 40 mg de fluoxétine par jour ou de 20 mg à 40 mg de fluoxétine par jour plus 1 séance hebdomadaire de PTI. À cause de la non-observance, 7 patients ont abandonné. Nous avons évalué les 32 patients qui ont terminé les 24 semaines de traitement au départ, à la 12 e semaine et à la 24 e semaine, à l'aide des entrevues semi-structurées des caractéristiques cliniques, c'est-à-dire l'Impression clinique globale (CGI), l'échelle de dépression de Hamilton (HDRS), l'échelle d'anxiété de Hamilton (HARS), et 2 questionnaires autodéclarés, soit le profil de satisfaction (SAT-P) quant à la qualité de vie, et l'inventaire des problèmes interpersonnels en 64 items (IIP-64). Nous avons mené une analyse statistique au moyen de modèles linéaires généraux univariés avec 2 facteurs : la durée et le type de traitement.
Résultats : Les changements de taux de rémission et les scores à la CGI et à la HARS ne différaient pas entre les traitements. La thérapie combinée était supérieure à la fluoxétine seulement, selon les changements des scores à la HDRS, les changements des scores du fonctionnement psychologique et du fonctionnement social au SAT-P, et les changements des scores de vindicatif ou égocentrique, froid ou distant, importun ou indigent, et socialement inhibé au IIP-64.
Conclusions :
La thérapie combinée avec la PTI est plus efficace que la thérapie aux antidépresseurs seulement, tant pour les symptômes de la dépression majeure que pour les dimensions de la qualité de vie et du fonctionnement interpersonnel.
